





# Fachgespräch 12/07/2021: Impfung & Immunität




# Dynamik der Serum-Antikörper nach mRNA1273 (moderna) Impfung

● 18–55 yr of age    + 56–70 yr of age    \* ≥71 yr of age

**A** Receptor-Binding Domain ELISA




**B** Pseudovirus Neutralization Assay





Doria-Rose et al.  
N Engl J Med 2021; 384:2259-2261






# Dynamik der Serum-IgG & Keimzentrumszellen nach BNT162b2 Impfung



# Stabilität der Immunantwort nach ChAdOx1-nCoV19(AZ) – single dose




# Neutralisierende Antikörper 29 & 239 Tage nach Ad26.COV2.S (J&J)





# Abgeschwächte Impfantwort (BNT) bei Älteren (>80J.)


■ young  
■ elderly



# Abgeschwächte Impfantwort (BNT) bei Älteren (>80J.)



# Altersabhängigkeit der Neutralisationskapazität nach BNT162b2 Impfung



Wall E, *Lancet* June 03 2021


[https://doi.org/10.1016/S0140-6736\(21\)01290-3](https://doi.org/10.1016/S0140-6736(21)01290-3)



# Effekt einer homologen dritten Impfung (Booster) mit mRNA1237 (moderna)


n=20 / group

5.9 to 7.5 months  
after 2<sup>nd</sup> dose




# Effekt einer homologen dritten Impfung (Booster) mit BNT bei Organtransplantierten

**A** Prevalence of Anti-SARS-CoV-2 Antibodies



**B** Anti-SARS-CoV-2 Antibody Titers



# Effekt einer homologen dritten Impfung mit ChAdOx1-nCoV19

